Bristol Myers Squibb Company's Inrebic has become the first new therapy in the EU in nearly a decade to get the green light for myelofibrosis (MF), joining Novartis AG and Incyte Corporation's Jakavi as an approved treatment for the bone marrow disorder.
BMS Buoyed By EU Approval Of Myelofibrosis Drug
Inrebic Came From Celgene Acquisition
There have been lots of twists and turns on the development path for Inrebic which is now the second JAK inhibitor to be approved in the EU for MF since the blockbuster Jakavi was cleared in 2012.
